Brief: Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction In ORIGIN Phase 3 Trial In Adults With IgA Nephropathy
02/06/2025 13:25
June 2 (Reuters) - Vera Therapeutics Inc VERA.O: VERA THERAPEUTICS ANNOUNCES ATACICEPT ACHIEVED 46% PROTEINURIA REDUCTION IN ORIGIN PHASE 3 TRIAL IN ADULTS WITH IGA NEPHROPATHY VERA THERAPEUTICS INC - TO SUBMIT BLA FOR ATACICEPT TO FDA IN 4Q 2025 VERA THERAPEUTICS INC - ATACICEPT SAFETY PROFILE FAVORABLE AND COMPARABLE TO PLACEBO VERA THERAPEUTICS INC: PRIMARY ENDPOINT WAS MET IN ORIGIN PHASE 3 TRIAL OF ATACICEPT Source text: ID:nGNX8QnTwP Further company coverage: VERA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vera Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Forgent Power, Vera Bradley, Wells Fargo
U.S. STOCKS ON THE MOVE-Forgent Power, Vera Bradley, Wells Fargo
U.S. STOCKS ON THE MOVE-Eli Lilly, Waystar, Wells Fargo
U.S. STOCKS ON THE MOVE-Eli Lilly, Waystar, Sysco
Vera Therapeutics gains after kidney disease drug meets goals in confirmatory trial